Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Industry Estimation 15
Figure 4. Asia Pacific Industry Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 17
Figure 5. Asia Pacific Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 20
Figure 6. Impact of COVID-19 on Business 24
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Pharmaceutical Manufacturing Industry 26
Figure 8. Primary Restraints and Impact Factors of Asia Pacific Pharmaceutical Manufacturing Industry 29
Figure 9. Investment Opportunity Analysis 33
Figure 10. Porter’s Fiver Forces Analysis of Asia Pacific Pharmaceutical Manufacturing Industry 36
Figure 11. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Formulation, 2020-2027, % of Revenue 41
Figure 12. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Formulation, Value ($ bn) and Share (%) 41
Figure 13. Asia Pacific Pharmaceutical Manufacturing Industry: Tablets, 2017-2027, $ bn 42
Figure 14. Asia Pacific Pharmaceutical Manufacturing Industry: Capsules, 2017-2027, $ bn 43
Figure 15. Asia Pacific Pharmaceutical Manufacturing Industry: Injectable, 2017-2027, $ bn 44
Figure 16. Asia Pacific Pharmaceutical Manufacturing Industry: Sprays, 2017-2027, $ bn 45
Figure 17. Asia Pacific Pharmaceutical Manufacturing Industry: Suspensions, 2017-2027, $ bn 46
Figure 18. Asia Pacific Pharmaceutical Manufacturing Industry: Powders, 2017-2027, $ bn 47
Figure 19. Asia Pacific Pharmaceutical Manufacturing Industry: Other Formulations, 2017-2027, $ bn 48
Figure 20. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration, 2020-2027, % of Revenue 50
Figure 21. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Route of Administration, Value ($ bn) and Share (%) 50
Figure 22. Asia Pacific Pharmaceutical Manufacturing Industry: Oral Medicine, 2017-2027, $ bn 51
Figure 23. Asia Pacific Pharmaceutical Manufacturing Industry: Topical Medicine, 2017-2027, $ bn 52
Figure 24. Asia Pacific Pharmaceutical Manufacturing Industry: Parenteral Medicine, 2017-2027, $ bn 53
Figure 25. Asia Pacific Pharmaceutical Manufacturing Industry: Inhalations, 2017-2027, $ bn 54
Figure 26. Asia Pacific Pharmaceutical Manufacturing Industry: Other Routes of Administration, 2017-2027, $ bn 55
Figure 27. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Age Group, 2020-2027, % of Revenue 56
Figure 28. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Age Group, Value ($ bn) and Share (%) 57
Figure 29. Asia Pacific Pharmaceutical Manufacturing Industry: Children & Adolescents, 2017-2027, $ bn 58
Figure 30. Asia Pacific Pharmaceutical Manufacturing Industry: Adults, 2017-2027, $ bn 59
Figure 31. Asia Pacific Pharmaceutical Manufacturing Industry: Geriatric, 2017-2027, $ bn 60
Figure 32. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application, 2020-2027, % of Revenue 62
Figure 33. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%) 62
Figure 34. Asia Pacific Pharmaceutical Manufacturing Industry: Cardiovascular Diseases, 2017-2027, $ bn 63
Figure 35. Asia Pacific Pharmaceutical Manufacturing Industry: Pain, 2017-2027, $ bn 64
Figure 36. Asia Pacific Pharmaceutical Manufacturing Industry: Diabetes, 2017-2027, $ bn 65
Figure 37. Asia Pacific Pharmaceutical Manufacturing Industry: Cancer, 2017-2027, $ bn 66
Figure 38. Asia Pacific Pharmaceutical Manufacturing Industry: Respiratory Diseases, 2017-2027, $ bn 67
Figure 39. Asia Pacific Pharmaceutical Manufacturing Industry: Neurological Diseases, 2017-2027, $ bn 68
Figure 40. Asia Pacific Pharmaceutical Manufacturing Industry: Orthopedics, 2017-2027, $ bn 69
Figure 41. Asia Pacific Pharmaceutical Manufacturing Industry: Other Applications, 2017-2027, $ bn 70
Figure 42. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type, 2020-2027, % of Revenue 71
Figure 43. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%) 72
Figure 44. Asia Pacific Pharmaceutical Manufacturing Industry: Branded Prescription Drugs, 2017-2027, $ bn 73
Figure 45. Asia Pacific Pharmaceutical Manufacturing Industry: Generic Prescription Drugs, 2017-2027, $ bn 74
Figure 46. Asia Pacific Pharmaceutical Manufacturing Industry: OTC Drugs, 2017-2027, $ bn 75
Figure 47. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channels, 2020-2027, % of Revenue 76
Figure 48. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Distribution Channels, Value ($ bn) and Share (%) 77
Figure 49. Asia Pacific Pharmaceutical Manufacturing Industry: Retail Channels, 2017-2027, $ bn 78
Figure 50. Asia Pacific Pharmaceutical Manufacturing Industry: Non-retail Channels, 2017-2027, $ bn 79
Figure 51. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2020-2027, % of Revenue 81
Figure 52. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Manufacturing Facility, Value ($ bn) and Share (%) 81
Figure 53. Asia Pacific Pharmaceutical Manufacturing Industry: In-house Facility, 2017-2027, $ bn 82
Figure 54. Asia Pacific Pharmaceutical Manufacturing Industry: Outsourced Facility, 2017-2027, $ bn 83
Figure 55. Breakdown of APAC Pharmaceutical Manufacturing Industry by Country, 2020 and 2027, % of Revenue 85
Figure 56. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%) 86
Figure 57. Pharmaceutical Manufacturing Industry in China, 2017-2027, $ bn 87
Figure 58. Pharmaceutical Manufacturing Industry in Japan, 2017-2027, $ bn 90
Figure 59. Pharmaceutical Manufacturing Industry in India, 2017-2027, $ bn 92
Figure 60. Pharmaceutical Manufacturing Industry in Australia, 2017-2027, $ bn 94
Figure 61. Pharmaceutical Manufacturing Industry in South Korea, 2017-2027, $ bn 96
Figure 62. Pharmaceutical Manufacturing Industry in Rest of APAC, 2017-2027, $ bn 98
Figure 63. Growth Stage of Asia Pacific Industrial Robot Software Industry over the Forecast Period 100
?
Asia Pacific pharmaceutical manufacturing industry will grow by 14.8% annually with a total addressable market cap of $1,034.6 billion over 2021-2027 driven by increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure amid the COVID-19 pandemic. Highlighted with 33 tables and 63 figures, this 130-page report “Asia Pacific Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmaceutical manufacturing industry and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate/forecast from 2020 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Industry Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Industry Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific industry is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical manufacturing industry in every aspect of the classification from perspectives of Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country. Based on Formulation, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Tablets • Capsules • Injectable • Sprays • Suspensions • Powders • Other Formulations Based on Route of Administration, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Oral Medicine • Topical Medicine • Parenteral Medicine • Inhalations • Other Routes of Administration Based on Age Group, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Children & Adolescents • Adults • Geriatric Based on Therapeutic Application, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Cardiovascular Diseases • Pain • Diabetes • Cancer • Respiratory Diseases • Neurological Diseases • Orthopedics • Other Applications Based on Drug Type, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Branded Prescription Drugs • Generic Prescription Drugs • OTC Drugs Based on Distribution Channels, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Retail Channels • Non-retail Channels Based on Manufacturing Facility, the Asia Pacific industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • In-house Facility • Outsourced Facility Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual production value are available for 2017-2027. The breakdown of key national industry by Formulation, Route of Administration, and Drug Type over the forecast years is also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including industry leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific pharmaceutical manufacturing industry are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Aenova Group Amgen AstraZeneca Catalent Inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences GlaxoSmithKline plc Johnson & Johnson Lonza Group Lupin Merck & Co., Inc. Novartis AG Novo Nordisk Pfizer, Inc. Roche Sanofi SA Takeda (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More